110 related articles for article (PubMed ID: 17276055)
1. Orally active 4-amino-5-diarylurea-furo[2,3-d]pyrimidine derivatives as anti-angiogenic agent inhibiting VEGFR2 and Tie-2.
Miyazaki Y; Tang J; Maeda Y; Nakano M; Wang L; Nolte RT; Sato H; Sugai M; Okamoto Y; Truesdale AT; Hassler DF; Nartey EN; Patrick DR; Ho ML; Ozawa K
Bioorg Med Chem Lett; 2007 Mar; 17(6):1773-8. PubMed ID: 17276055
[TBL] [Abstract][Full Text] [Related]
2. Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors.
Miyazaki Y; Matsunaga S; Tang J; Maeda Y; Nakano M; Philippe RJ; Shibahara M; Liu W; Sato H; Wang L; Nolte RT
Bioorg Med Chem Lett; 2005 May; 15(9):2203-7. PubMed ID: 15837294
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.
Yang LL; Li GB; Ma S; Zou C; Zhou S; Sun QZ; Cheng C; Chen X; Wang LJ; Feng S; Li LL; Yang SY
J Med Chem; 2013 Feb; 56(4):1641-55. PubMed ID: 23362959
[TBL] [Abstract][Full Text] [Related]
4. Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor.
Hodous BL; Geuns-Meyer SD; Hughes PE; Albrecht BK; Bellon S; Bready J; Caenepeel S; Cee VJ; Chaffee SC; Coxon A; Emery M; Fretland J; Gallant P; Gu Y; Hoffman D; Johnson RE; Kendall R; Kim JL; Long AM; Morrison M; Olivieri PR; Patel VF; Polverino A; Rose P; Tempest P; Wang L; Whittington DA; Zhao H
J Med Chem; 2007 Feb; 50(4):611-26. PubMed ID: 17253678
[TBL] [Abstract][Full Text] [Related]
5. Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase.
Cee VJ; Albrecht BK; Geuns-Meyer S; Hughes P; Bellon S; Bready J; Caenepeel S; Chaffee SC; Coxon A; Emery M; Fretland J; Gallant P; Gu Y; Hodous BL; Hoffman D; Johnson RE; Kendall R; Kim JL; Long AM; McGowan D; Morrison M; Olivieri PR; Patel VF; Polverino A; Powers D; Rose P; Wang L; Zhao H
J Med Chem; 2007 Feb; 50(4):627-40. PubMed ID: 17253679
[TBL] [Abstract][Full Text] [Related]
6. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases.
Dandu R; Zulli AL; Bacon ER; Underiner T; Robinson C; Chang H; Miknyoczki S; Grobelny J; Ruggeri BA; Yang S; Albom MS; Angeles TS; Aimone LD; Hudkins RL
Bioorg Med Chem Lett; 2008 Mar; 18(6):1916-21. PubMed ID: 18308565
[TBL] [Abstract][Full Text] [Related]
8. Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.
Dai Y; Guo Y; Frey RR; Ji Z; Curtin ML; Ahmed AA; Albert DH; Arnold L; Arries SS; Barlozzari T; Bauch JL; Bouska JJ; Bousquet PF; Cunha GA; Glaser KB; Guo J; Li J; Marcotte PA; Marsh KC; Moskey MD; Pease LJ; Stewart KD; Stoll VS; Tapang P; Wishart N; Davidsen SK; Michaelides MR
J Med Chem; 2005 Sep; 48(19):6066-83. PubMed ID: 16162008
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent.
Hudkins RL; Becknell NC; Zulli AL; Underiner TL; Angeles TS; Aimone LD; Albom MS; Chang H; Miknyoczki SJ; Hunter K; Jones-Bolin S; Zhao H; Bacon ER; Mallamo JP; Ator MA; Ruggeri BA
J Med Chem; 2012 Jan; 55(2):903-13. PubMed ID: 22148921
[TBL] [Abstract][Full Text] [Related]
10. Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors.
Harris PA; Cheung M; Hunter RN; Brown ML; Veal JM; Nolte RT; Wang L; Liu W; Crosby RM; Johnson JH; Epperly AH; Kumar R; Luttrell DK; Stafford JA
J Med Chem; 2005 Mar; 48(5):1610-9. PubMed ID: 15743202
[TBL] [Abstract][Full Text] [Related]
11. Design and effective synthesis of novel templates, 3,7-diphenyl-4-amino-thieno and furo-[3,2-c]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases.
Miyazaki Y; Nakano M; Sato H; Truesdale AT; Stuart JD; Nartey EN; Hightower KE; Kane-Carson L
Bioorg Med Chem Lett; 2007 Jan; 17(1):250-4. PubMed ID: 17027260
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.
Weiss MM; Harmange JC; Polverino AJ; Bauer D; Berry L; Berry V; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1668-80. PubMed ID: 18324759
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo[3,2-d]pyrimidine derivatives: novel VEGFR2 kinase inhibitors binding to inactive kinase conformation.
Oguro Y; Miyamoto N; Okada K; Takagi T; Iwata H; Awazu Y; Miki H; Hori A; Kamiyama K; Imamura S
Bioorg Med Chem; 2010 Oct; 18(20):7260-73. PubMed ID: 20833055
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase.
Sammond DM; Nailor KE; Veal JM; Nolte RT; Wang L; Knick VB; Rudolph SK; Truesdale AT; Nartey EN; Stafford JA; Kumar R; Cheung M
Bioorg Med Chem Lett; 2005 Aug; 15(15):3519-23. PubMed ID: 15990302
[TBL] [Abstract][Full Text] [Related]
15. 8-THP-DHI analogs as potent Type I dual TIE-2/VEGF-R2 receptor tyrosine kinase inhibitors.
Hudkins RL; Zulli AL; Underiner TL; Angeles TS; Aimone LD; Meyer SL; Pauletti D; Chang H; Fedorov EV; Almo SC; Fedorov AA; Ruggeri BA
Bioorg Med Chem Lett; 2010 Jun; 20(11):3356-60. PubMed ID: 20430619
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors.
Hasegawa M; Nishigaki N; Washio Y; Kano K; Harris PA; Sato H; Mori I; West RI; Shibahara M; Toyoda H; Wang L; Nolte RT; Veal JM; Cheung M
J Med Chem; 2007 Sep; 50(18):4453-70. PubMed ID: 17676829
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors.
Potashman MH; Bready J; Coxon A; DeMelfi TM; DiPietro L; Doerr N; Elbaum D; Estrada J; Gallant P; Germain J; Gu Y; Harmange JC; Kaufman SA; Kendall R; Kim JL; Kumar GN; Long AM; Neervannan S; Patel VF; Polverino A; Rose P; Plas Sv; Whittington D; Zanon R; Zhao H
J Med Chem; 2007 Sep; 50(18):4351-73. PubMed ID: 17696416
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino-linked thiazolo[5,4-d]pyrimidine and thiazolo[5,4-b]pyridine derivatives.
Hirose M; Okaniwa M; Miyazaki T; Imada T; Ohashi T; Tanaka Y; Arita T; Yabuki M; Kawamoto T; Tsutsumi S; Sumita A; Takagi T; Sang BC; Yano J; Aertgeerts K; Yoshida S; Ishikawa T
Bioorg Med Chem; 2012 Sep; 20(18):5600-15. PubMed ID: 22883026
[TBL] [Abstract][Full Text] [Related]
19. Novel C-3 N-urea, amide, and carbamate dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs as potent TIE-2 and VEGF-R2 dual inhibitors.
Becknell NC; Zulli AL; Angeles TS; Yang S; Albom MS; Aimone LD; Robinson C; Chang H; Hudkins RL
Bioorg Med Chem Lett; 2006 Oct; 16(20):5368-72. PubMed ID: 16890434
[TBL] [Abstract][Full Text] [Related]
20. N-phenyl-N'-[4-(5H-pyrrolo[3,2-d]pyrimidin-4-yloxy)phenyl]ureas as novel inhibitors of VEGFR and FGFR kinases.
Oguro Y; Miyamoto N; Takagi T; Okada K; Awazu Y; Miki H; Hori A; Kamiyama K; Imamura S
Bioorg Med Chem; 2010 Oct; 18(20):7150-63. PubMed ID: 20833551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
